SelectScience
Join Free
NewsLife Sciences

Vizgen showcases cellular and subcellular tumor characterization with new PanCancer Pathways Panel

Vizgen
18 Apr 2023
Jemima Arnold
Editorial Assistant

Industry news

At the American Association for Cancer Research (AACR) 2023 Annual Meeting in Florida, USA Vizgen, launched the MERSCOPE® PanCancer Pathways Panel.

The PanCancer Pathways Panel features a list of genes targeting canonical signaling pathways of cancer and is constructed using recognized oncology databases including OncoKB®, MutSig, the Cancer Genome Atlas, and Hallmarks of Cancer to ensure the inclusion of critical cancer genes. The Panel provides a key tool for researchers to study tumor behavior at cellular and subcellular levels across multiple different types of cancers.

The PanCancer Pathways Panel features:

  • Characterization of major oncology signaling pathways including RAS/RTK, PI3K, NOTCH, MYC, Cell Cycle, HIPPO
  • Inclusion of cell type markers to identify healthy and disease states
  • Compatibility across multiple cancer types

Vizgen also showcased data generated using the new MERSCOPE PanCancer Pathways Panel. The data demonstrates the ability of the MERSCOPE Platform to characterize individual cells in a wide range of human tumor types, including breast, colon, prostate, ovarian, lung and liver cancers. Analysis of expression patterns in tumor cells highlights the panels’ ability to accurately reproduce known transcriptional signatures of hepatocellular carcinoma.

“While Vizgen is known for the customizability of our platform, this pre-designed panel along with our PanNeuro Cell Type Panel represent an ideal starting point for researchers who are looking for convenient off-the-shelf options to explore adding spatial genomic capabilities into their research,” said Terry Lo, President and CEO of Vizgen.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>

Links

Vizgen

Tags

Point-of-CarePoint-of-Care Testing (POCT) or Near Patient Testing (NPT) products are available for urine, blood and other clinical chemistry analyses. POCT includes: blood glucose testing, blood gas and electrolytes analysis, rapid coagulation testing (PT / INR), rapid cardiac markers diagnostics, drugs of abuse screening, urine strips testing, pregnancy testing, fecal occult blood analysis, food pathogens screening, hemoglobin diagnostics, infectious disease testing and cholesterol screening.BiomarkersBiomarkers are biological markers which can be measured and evaluated to indicate a biological state. The use of biomarkers in research and diagnosis can indicate a normal or disease state or drug response of cells / tissues. Biomarkers include genetic markers, cell surface markers such as antigens, antibodies or receptors and secreted molecules such as cytokines. An assay system is required for identification of biomarkers. :SignalingTumorsTumor research focuses on understanding abnormal cell growth that leads to cancer. Identifying biomarkers, studying tumor microenvironments, and developing targeted therapies are critical for advancing cancer treatment. Early detection and personalized treatment options are key to improving outcomes for patients. Browse our peer-reviewed product directory to explore tools for tumor research, diagnostics, and cancer therapies; compare products, read customer reviews, and get pricing directly from manufacturers.AACRThe American Association for Cancer Research (AACR) is a leading organization focused on cancer research and treatment. It provides a platform for scientists, healthcare professionals, and industry leaders to share knowledge and collaborate in the fight against cancer.Cancer ResearchAlthough cancer is often referred to as a single condition, it actually consists of more than 100 different diseases. Microscopy, mass spectrometry, high throughput sequencing and flow cytometry are some of the most common techniques employed in cancer research labs.

Related articles

Vizgen showcases cellular and subcellular tumor characterization with new PanCancer Pathways Panel